Journal article
Incidence and prevalence of NMOSD in Australia and New Zealand
W Bukhari, KM Prain, P Waters, M Woodhall, CM O'Gorman, L Clarke, RA Silvestrini, CS Bundell, D Abernethy, S Bhuta, S Blum, M Boggild, K Boundy, BJ Brew, M Brown, WJ Brownlee, H Butzkueven, WM Carroll, C Chen, A Coulthard Show all
Journal of Neurology Neurosurgery and Psychiatry | BMJ PUBLISHING GROUP | Published : 2017
Abstract
Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From thi..
View full abstractGrants
Funding Acknowledgements
This project was undertaken by the Australia and New Zealand Neuromyelitis Optica (ANZ NMO) Collaboration and was supported by funding from Multiple Sclerosis Research Australia, the Brain Foundation, Griffith University and the Gold Coast Hospital Foundation. The work in Oxford was supported by the National Health Service National Specialised Commissioning Group for Neuromyelitis Optica and the National Institute for Health Research Oxford Biomedical Research Centre.